Antithrombin-lowering in hemophilia: a closer look at fitusiran

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Sanofi Revises Fitusiran Dosing Regimen to Mitigate Risk of Vascular Thrombosis

ALN-AT3SC - Creative Biolabs

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet

Full article: An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B

WO2021262695A1 - Methods and compositions for treating hemophilia - Google Patents

A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC

Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors

Fitusiran Emerges as a Potential Pan-Hemophilia Rebalancing Agent

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review - Verhagen - 2022 - Journal of Thrombosis and Haemostasis - Wiley Online Library

Fitusiran Prevents Bleeds in Hemophilia A or B Over Long Term, Study Finds

Hemophilia therapy: the future has begun

Hemophilia as a blueprint for gene therapy

RNAi for the treatment of people with hemophilia

RNAi for the treatment of people with hemophilia